Array BioPharma (ARRY) has been under a strong bear grip, hence the stock is down -0.32% when compared to the S&P 500 in the past 4 weeks. However, in the near-term, buying emerged at lower levels and the stock has outperformed the S&P 500 by 3.38% in the past 1 week. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 3.31% in the last 1 week, and is up 3.03% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.
The stock has recorded a 20-day Moving Average of 1.66% and the 50-Day Moving Average is 5.81%. Array BioPharma Inc. is up 17.24% in the last 3-month period. Year-to-Date the stock performance stands at -11.37%.
Array BioPharma (NASDAQ:ARRY): On Fridays trading session , Opening price of the stock was $3.76 with an intraday high of $3.81. The bears continued to sell at higher levels and eventually sold the stock down to an intraday low of $3.65. However, the stock managed to close at $3.74, a loss of 0.80% for the day. On the previous day, the stock had closed at $3.77. The total traded volume of the day was 925,491 shares.
Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule drugs to treat patients afflicted with cancer. The Companys wholly owned clinical stage drugs include Filanesib in Phase II clinical trials, is indicated for Kinesin spindle protein (KSP), inhibitor for MM; ARRY-797 in Phase II clinical trials, indicated for p38 inhibitor for Lamin A/C-related dilated cardiomyopathy (LMNA-DCM); ARRY-502 in Phase II clinical trials, indicated for CRTh2 antagonist for asthma, and ARRY-614 in Phase I clinical trials, is indicated for p38/Tie2 dual inhibitor for myelodysplastic syndromes (MDS). In addition, the Company has 11 ongoing partner-funded clinical programs, including two MEK inhibitors, which are both in Phase III clinical trials, binimetinib with Novartis and selumetinib with AstraZeneca.